General Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancersBy Healthcare Propulsion StaffSeptember 15, 20260 Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and…
General Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosisBy Healthcare Propulsion StaffSeptember 10, 20260 Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with…
